Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Virginia STEM News.
Press releases published on October 20, 2025
FIRST IMPRESSION ORTHODONTICS WELCOMES DR. JENNA SCHNEIDER TO THE TEAM
Bringing advanced orthodontic expertise and a love for patient care, Dr. Schneider joins Alexandria’s trusted FIO team. ALEXANDRIA, VA, UNITED STATES, October 20, 2025 /EINPresswire.com/ -- First Impression Orthodontics (FIO), led by orthodontist Dr. …
NovaBay Pharmaceuticals, Inc. Regains Compliance with NYSE American Continued Listing Standards
EMERYVILLE, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) ("NovaBay" or the "Company") announces that it has regained compliance with the NYSE American’s continued listing standards. As previously disclosed, …
XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
CALGARY, Alberta, Oct. 20, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat …
atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares
NEW YORK and AMSTERDAM, Oct. 20, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health disorders, today announced that, on October 20, 2025, …
Constellation Software Inc. Announces Release Date for Third Quarter Results
TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Constellation Software Inc. (TSX:CSU) announced today it intends to release its third quarter results on November 7, 2025. The Company’s quarterly results will be disseminated via press release and made available …
Topicus.com Inc. Announces Release Date for Third Quarter Results
TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Topicus.com Inc. (TSXV:TOI) announced today it intends to release its third quarter results on November 4, 2025. The Company’s quarterly results will be disseminated via press release and made available on the …
DIH Announces Fiscal 2025 Fourth Quarter and Fiscal Year End Financial Results
NORWELL, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- DIH Holding US, Inc. (“DIH” or the “Company”) (NASDAQ:DHAI), a global provider of advanced robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to …
No Limits and Automae announce a strategic alliance to accelerate automation for SMEs in France and Switzerland
Geneva, Switzerland, Oct. 20, 2025 (GLOBE NEWSWIRE) -- No Limits, an ecosystem for business enablement and executive coaching, announces a strategic partnership with Automae, a no‑code automation consultancy founded by Théo Jim. The alliance combines …
NowVertical to feature in Fireside Chat at the Planet MicroCap Showcase: TORONTO on Wednesday, October 22, 2025
Fireside Chat with Stifel Financial Corp. will be hosted at 2:00PM EDT Wednesday, October 22, 2025 in partnership with MicroCapClub 1x1 Meetings scheduled on Thursday, October 23, 2025 TORONTO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- NowVertical Group Inc. ( …
3 E Network Technology Group Limited Announces Closing of US$1.5 Million Convertible Promissory Note Offering
HONG KONG, Oct. 20, 2025 (GLOBE NEWSWIRE) -- 3 E Network Technology Group Limited (Nasdaq: MASK) (the “Company” or “3e Network”), a business-to-business (“B2B”) information technology (“IT”) business solutions provider, today announced the closing of …
Bio Usawa Announces Approval of BioUcenta™ by the Rwandan FDA
KIGALI, Rwanda and SAN FRANCISCO, Oct. 20, 2025 (GLOBE NEWSWIRE) -- The Rwanda Food and Drugs Authority has granted market approval for Bio Usawa Biotechnology Ltd.’s (Bio Usawa) BioUcenta™, a biosimilar of Lucentis® (ranibizumab) for the treatment of …
Teva and Prestige Biopharma Enter License Agreement for Tuznue® Commercialization in Europe
Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue®, a biosimilar to Herceptin® (trastuzumab) Tuznue® received European Commission (EC) marketing authorization in September 2024 Partnership brings …
Commerce to Announce Third Quarter 2025 Financial Results on November 6, 2025
AUSTIN, Texas, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Commerce.com, Inc. (Nasdaq: CMRC) (formerly BigCommerce Holdings, Inc.), a provider of an open, intelligent ecosystem of technology solutions that empower businesses to unlock data potential and deliver …
Onco360® Has Been Selected as a Specialty Pharmacy Partner for PHYRAGO™ (dasatinib)
LOUISVILLE, Ky., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Cycle Pharmaceuticals Ltd. for Phyrago™ (dasatinib) tablets. Phyrago is a kinase inhibitor …
CLEAR and Wellstar Health System Modernize the Patient Experience Using CLEAR1’s Digital Check-In
NEW YORK and ATLANTA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- CLEAR (NYSE: YOU), the secure identity company, and Wellstar Health System (“Wellstar”), are dramatically improving the patient experience and saving hundreds of staff hours through a partnership that …
Cycurion, Inc. Announces Nasdaq Delisting Determination Letter
MCLEAN, Va., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leading cybersecurity solutions provider, announced today that it received a Delisting Determination Letter from the staff of Nasdaq Listing …
Lirum Therapeutics Announces FDA “Study May Proceed” Letter Enabling Inclusion of LX-101 in the RAPID Platform Clinical Trial for Ewing Sarcoma and Desmoplastic Small Round Cell Tumor
New York, NY, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on the treatment of debilitating diseases, announced today that the U.S. Food and Drug Administration (FDA) …
Neuphoria Therapeutics Provides Update on AFFIRM-1 Phase 3 Trial Evaluating BNC210 for the Acute Treatment of Social Anxiety Disorder
AFFIRM-1 trial did not meet primary endpoint or secondary endpoints Company to conduct strategic review of portfolio and business operations BURLINGTON, Mass., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. (Nasdaq: NEUP) (“Neuphoria” or the …
La FDA autorise le système d’implant de pied et de cheville SINAPTIC® de SINTX Technologies
Fabriqué aux États-Unis et désormais approuvé par la FDA, ce système d’implant conçu par SINTX s’ouvre les portes d’un marché américain valorisé à plusieurs milliards de dollars SALT LAKE CITY, Utah, 20 oct. 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc …
SINTX Technologies מקבלת אישור FDA לטכנולוגיית השתלת כף רגל וקרסול SINAPTIC®
ה-FDA אישר ומערכת שתלים מתוצרת ארה"ב- ממצבת את SINTX בכניסה לשוק האמריקני של מיליארד דולר סולט לייק סיטי, יוטה, Oct. 20, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (נאסד"ק: SINT) ("SINTX" או "החברה"), חדשנית קרמיקה מתקדמת המתמחה ביישומים ביו-רפואיים …